Drugs / Neoantigen Peptide Vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05098210 | Jun 2022 → Nov 2027 expected | acral lentiginous melanoma, female breast carcinoma, hormone receptor-positive breast cancer, malignant conjunctival melanoma +3 | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03956056 | Feb 2020 → Jul 2022 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05269381 | Mar 2022 → Mar 2028 expected | breast adenocarcinoma, carcinosarcoma of the corpus uteri, cervical carcinoma, cutaneous melanoma +16 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05749627 | Apr 2023 → Dec 2025 overdue | cancer | The First Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03956056 ↗ |
| Modality | Vaccine | “neoantigen peptide vaccines” NCT03956056 ↗ |
| Route | Subcutaneous | “by subcutaneous (SC) injection” NCT03956056 ↗ |